[Anti-tumor immunotherapy based on dendritic cells]. / L'immunothérapie anti-tumorale à base de cellules dendritiques.
J Soc Biol
; 195(1): 19-23, 2001.
Article
en Fr
| MEDLINE
| ID: mdl-11530495
ABSTRACT
In cancer immunotherapy, the use of dendritic cells (DC) loaded with tumor-associated antigens (TAA) emerged as a promising strategy. We initiated 3 pilot clinical trials with immunological endpoints using TAA loaded autologous DC. These trials showed that this approach was safe and associated with the induction of potent TAA specific IFN-gamma responses, which were transient despite the providing a further help through KLH presentation. Subcutaneous (s.c.) IL-2 administration was associated with long-lasting TAA specific IL-5 production. Clinical responses were observed in about 1/3 of the patients. Further improvements will take advantage of the use of a new type of DC cells (IL-3/IFN-beta DC) and of tumor cell-DC hybrids.
Search on Google
Banco de datos:
MEDLINE
Asunto principal:
Células Dendríticas
/
Inmunoterapia Adoptiva
/
Antígenos de Neoplasias
/
Neoplasias
Límite:
Humans
Idioma:
Fr
Año:
2001
Tipo del documento:
Article